New insights into the pathophysiology of methylmalonic acidemia

Authors:
Publisher website
Google Scholar
Abstract
Methylmalonic acidemia (MMA) is a severe inborn error of metabolism that is characterized by pleiotropic metabolic perturbations and multiorgan pathology. Treatment options are limited and non‐curative as the underlying causative molecular mechanisms remain unknown. While earlier studies have focused on the potential direct toxicity of metabolites such as methylmalonic and propionic acid as a mechanism to explain disease pathophysiology, new observations have revealed that aberrant acylation, specifically methylmalonylation, is a characteristic feature of MMA. The mitochondrial sirtuin enzyme SIRT5 is capable of recognizing and removing this PTM, however, reduced protein levels of SIRT5 along with other mitochondrial SIRTs 3 and 4 in MMA and potentially reduced function of all three indicates aberrant acylation may require clinical intervention. Therefore, targeting posttranslational modifications may represent a new therapeutic approach to treat MMA and related organic acidemias.
Funding Information
  • National Cancer Institute (1TZIABC011488‐ 09)
  • National Human Genome Research Institute (1ZIAHG200318‐16)
  • National Institute of General Medical Sciences (1FI2GM137781‐01)

This publication has 119 references indexed in Scilit: